Ziopharm Oncology Inc. (ZIOP) Given Buy Rating at Griffin Securities
Griffin Securities reissued their buy rating on shares of Ziopharm Oncology Inc. (NASDAQ:ZIOP) in a report released on Saturday morning. Griffin Securities currently has a $21.00 target price on the biotechnology company’s stock.
A number of other equities analysts also recently issued reports on the company. Zacks Investment Research cut Ziopharm Oncology from a buy rating to a hold rating in a report on Wednesday, October 12th. Wells Fargo & Co. raised Ziopharm Oncology from an underperform rating to a market perform rating in a report on Wednesday, August 10th. One research analyst has rated the stock with a sell rating, four have assigned a hold rating, one has given a buy rating and one has given a strong buy rating to the stock. The company has a consensus rating of Hold and an average price target of $9.75.
Ziopharm Oncology (NASDAQ:ZIOP) traded down 7.20% on Friday, reaching $6.32. The company’s stock had a trading volume of 2,499,442 shares. Ziopharm Oncology has a 12-month low of $4.45 and a 12-month high of $13.70. The company’s 50 day moving average price is $5.79 and its 200-day moving average price is $5.88. The stock’s market cap is $824.73 million.
Ziopharm Oncology (NASDAQ:ZIOP) last posted its quarterly earnings data on Wednesday, November 9th. The biotechnology company reported ($0.11) earnings per share for the quarter, meeting the Zacks’ consensus estimate of ($0.11). Ziopharm Oncology had a negative return on equity of 364.49% and a negative net margin of 2,276.89%. The company earned $1.60 million during the quarter, compared to analyst estimates of $1.45 million. During the same quarter last year, the company earned ($0.14) EPS. The firm’s revenue for the quarter was down 15.8% on a year-over-year basis. On average, equities analysts expect that Ziopharm Oncology will post ($1.32) EPS for the current year.
Several hedge funds have recently made changes to their positions in the stock. Advisor Group Inc. acquired a new position in shares of Ziopharm Oncology during the second quarter worth approximately $105,000. Royal Bank of Canada increased its position in shares of Ziopharm Oncology by 18.8% in the second quarter. Royal Bank of Canada now owns 19,235 shares of the biotechnology company’s stock worth $105,000 after buying an additional 3,046 shares during the period. Oppenheimer & Co. Inc. increased its position in shares of Ziopharm Oncology by 4.8% in the second quarter. Oppenheimer & Co. Inc. now owns 20,100 shares of the biotechnology company’s stock worth $110,000 after buying an additional 919 shares during the period. Cubist Systematic Strategies LLC acquired a new position in shares of Ziopharm Oncology during the second quarter worth approximately $114,000. Finally, Principal Financial Group Inc. increased its position in shares of Ziopharm Oncology by 5.5% in the second quarter. Principal Financial Group Inc. now owns 21,388 shares of the biotechnology company’s stock worth $117,000 after buying an additional 1,124 shares during the period. Hedge funds and other institutional investors own 44.07% of the company’s stock.
Ziopharm Oncology Company Profile
ZIOPHARM Oncology, Inc is a biopharmaceutical company. The Company is seeking to acquire, develop and commercialize, on its own or with partners, a portfolio of cancer therapies through synthetic immuno-oncology. Its clinical-stage product candidate, Ad-RTS-IL-12, is used with the oral activator veledimex.
Receive News & Stock Ratings for Ziopharm Oncology Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ziopharm Oncology Inc. and related stocks with our FREE daily email newsletter.